

36. Sharma P, Zargar-Shoshtari K, Caracciolo JT, et al. Sarcopenia as a predictor of overall survival after cytoreductive nephrectomy for metastatic renal cell carcinoma. *Urol Oncol Semin Orig Investig*. 2015; 33(8): 339.e17–339.e23. doi:10.1016/j.urolonc.2015. 01. 011.
37. Psutka SP. Personalizing preoperative risk stratification and refining patient selection for cytoreductive nephrectomy in metastatic renal cell carcinoma. *Cancer*. 2020; 126(17): 3912–3915. doi:10.1002/cncr.32993.
38. Ito H, Shioi K, Murakami T, et al. C-reactive protein in patients with advanced metastatic renal cell carcinoma: Usefulness in identifying patients most likely to benefit from initial nephrectomy. *BMC Cancer*. 2012; 12(1): 337. doi:10.1186/1471-2407-12-337.
39. Sakai I, Miyake H, Hinata N, Fujisawa M. Improved survival in patients with metastatic renal cell carcinoma undergoing cytoreductive nephrectomy in the era of targeted therapy. *Int J Clin Oncol*. 2014; 19(4): 674–678. doi:10.1007/s10147-013-0612-z.
40. Baum YS, Patil D, Huang JH, et al. Elevated preoperative neutrophil-to-lymphocyte ratio may be associated with decreased overall survival in patients with metastatic clear cell renal cell carcinoma undergoing cytoreductive nephrectomy. *Asian J Urol*. 2016; 3(1): 20–25. doi:10.1016/j.ajur.2015. 09. 004.
41. Peyton CC, Abel EJ, Chipollini J, et al. The Value of Neutrophil to Lymphocyte Ratio in Patients Undergoing Cytoreductive Nephrectomy with Thrombectomy. *Eur Urol Focus*. 2020; 6(1): 104–111. doi:10.1016/j.euf.2018. 08. 023.
42. Day D, Kanjanapan Y, Kwan E, et al. Benefit from cytoreductive nephrectomy and the prognostic role of neutrophil-to-lymphocyte ratio in patients with metastatic renal cell carcinoma. *Intern Med J*. 2016; 46(11): 1291–1297. doi:10.1111/imj.13202.
43. Gu L, Ma X, Xie Y, et al. Pretreatment Lymphocyte to Monocyte Ratio is an Independent Prognostic Factor in Metastatic Clear Cell Renal Cell Carcinoma. *Clin Genitourin Cancer*. 2017; 15(3): e369–e377. doi:10.1016/j.clgc.2016. 12. 001.
44. Margulis V, Shariat SF, Rapoport Y, et al. Development of Accurate Models for Individualized Prediction of Survival After Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma. *Eur Urol*. 2013; 63(5): 947–952. doi:10.1016/j.eururo.2012. 11. 040.
45. Corcoran AT, Kaffenberger SD, Clark PE, et al. Hypoalbuminaemia is associated with mortality in patients undergoing cytoreductive nephrectomy. *BJU Int*. 2015; 116(3): 351–357. doi:10.1111/bju.12897.
46. Lee H, Kim YJ, Hwang EC, et al. Preoperative cholesterol level as a new independent predictive factor of survival in patients with metastatic renal cell carcinoma treated with cyto-reductive nephrectomy. *BMC Cancer*. 2017; 17(1): 364. doi:10.1186/s12885-017-3322-5.
47. Ishihara H, Kondo T, Yoshida K, et al. Evaluation of Preoperative Aspartate Transaminase/Alanine Transaminase Ratio as an Independent Predictive Biomarker in Patients With Metastatic Renal Cell Carcinoma Undergoing Cytoreductive Nephrectomy: A Propensity Score Matching Study. *Clin Genitourin Cancer*. 2017; 15(5): 598–604. doi:10.1016/j.clgc.2017. 04. 011.
48. Laukhtina E, Pradere B, D'Andrea D, et al. Association of preoperative serum De Ritis ratio with oncological outcomes in patients treated with cytoreductive nephrectomy for metastatic renal cell carcinoma. *Urol Oncol Semin Orig Investig*. 2020; 38(12): 936.e7–936.e14. doi:10.1016/j.urolonc.2020. 08. 013.
49. Culp SH, Schellhammer PF, Williams MB. Might Men Diagnosed with Metastatic Prostate Cancer Benefit from Definitive Treatment of the Primary Tumor? A SEER-Based Study. *Eur Urol*. 2014; 65(6): 1058–1066. doi:10.1016/j.eururo.2013. 11. 012.
50. McIntosh AG, Umbreit EC, Holland LC, et al. Optimizing patient selection for cytoreductive nephrectomy based on outcomes in the contemporary era of systemic therapy. *Cancer*. 2020; 126(17): 3950–3960. doi:10.1002/cncr.32991.